BioVersys AG
· ISIN: CH0210362643
· EQS - adhoc news
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News BioVersys AG
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
02 July 2025 07:00AM
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. July 2, 2025, 7am CEST.
The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates
Shionogi gets access to BioVersys’ proprietary ansamycin...
BioVersys AG
30 June 2025 07:00AM
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. June 30, 2025, 7am CEST
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, today a...
BioVersys AG
03 June 2025 07:00AM
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025
Ad hoc announcement pursuant to Art. 53 LR
.awlist1_1748898862_836540 { list-style:none; counter-set:awlistcounter24_0 }
.awlist1_1748898862_836540 > li:before { content:counter(awlistcounter24_0) '.'; counter-increment:awlistcounter24_0 }
.awlist2_1748898862_836540 { list-style:none; counter-set:awlistcounter24_1 }
.awlist2_1748898862_...
BioVersys AG
28 April 2025 07:00AM
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025
BioVersys AG
/ Key word(s): Conference
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025 28.04.2025 / 07:00 CET/CEST
Basel, Switzerland. April 28, 2025, 7am CET
Event titled “BV100 Shows Survival Benefit in Pha...
BioVersys AG
08 April 2025 07:00AM
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025
BioVersys AG
/ Key word(s): Conference
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025 08.04.2025 / 07:00 CET/CEST
Basel, Switzerland. April 08, 2025, 7am CEST.
Oral presentation on April 13, 2025, highlighting positive BV100 Phase 2 VABP trial read-out with excellent efficacy and safety data
Complementary...
BioVersys AG
31 March 2025 07:00AM
BIOVERSYS ANNOUNCES IMPORTANT BV100 PATENT GRANTED BY CHINESE PATENT OFFICE
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 31, 2025, 7am CET
Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the proprietary rifabutin IV formulation technology in China
BV100 patents have now been granted in over 25 countries, including in US, Europe, UK and China
BioVersys AG (SIX...
BioVersys AG
26 March 2025 07:00AM
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 26, 2025, 7am CET
BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy data
Alpibectir: Phase 2a EBA trial delivered very strong proof of concept
Preclinical candidates from BioVersys’ two proprietary platforms continue to progress
Full Year 2024 oper...
BioVersys AG
19 March 2025 07:00AM
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 19, 2025, 7am CET. Ad hoc announcement pursuant to Art. 53 LR
Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis (TB) trial, in combination with first-line TB ...
BioVersys AG
14 March 2025 07:00AM
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS
BioVersys AG
/ Key word(s): Annual Results
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS 14.03.2025 / 07:00 CET/CEST
Basel, Switzerland. March 14, 2025, 7am CET
BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of ...
BioVersys AG
10 March 2025 07:00AM
Bioversys announces partial exercise of over-allotment option
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 10, 2025, 7am CET. Ad hoc announcement pursuant to Art. 53 LR
Partial exercise of over-allotment option following end of stablization period in context of the company’s initial public offering (IPO)
An additional 47,862 new shares to be issued by BioVersys
BioVersys raised tot...
BioVersys AG
11 February 2025 07:00AM
BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE
BioVersys AG
/ Key word(s): Miscellaneous
BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE 11.02.2025 / 07:00 CET/CEST
Basel, Switzerland. February 11, 2025, 7am CET
BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead c...
BioVersys AG
06 February 2025 07:00AM
BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025
BioVersys AG
/ Key word(s): IPO
BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 06.02.2025 / 07:00 CET/CEST
__________
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMU...
BioVersys AG
More BioVersys AG related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 0 | - | - | Corporate Research |
| Directors Dealings | 0 | - | - | DD |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN